Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 2, 2015, Pages 319-324

  Rivera, F ^a   Massuti B ^b   Salcedo, M ^a   Sastre, J ^c,d   Martinez Galan J ^e   Valladares Ayerbes, M ^c   Serrano, R ^d,f   De Paredes, Ma L García ^g   Manzano, J L ^h   Galan M ⁱ   Alsina, M ^j   Yuste Izquierdo, A L ^b   Lopez C ^a   Diaz Rubio E ^c,d   Conde, V ^e   Reboredo, M ^c   Cano, Ma T ^d,f   Pachon V ^g   Aranda, E ^d,f  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HC San Carlos ^*  (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^f UNIVERSITY OF CÓRDOBA   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

more..

Author keywords

Advanced gastric cancer; Capecitabine; Docetaxel; Oxaliplatin; Suboptimal patients

Indexed keywords

CAPECITABINE; DOCETAXEL; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; FLUOROURACIL; PLATINUM COMPLEX; TAXOID;

ADULT; ADVANCED GASTRIC CANCER; AGED; ARTICLE; ASTHENIA; BACTEREMIA; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFECTION; KIDNEY FAILURE; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; BIOASSAY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; STOMACH NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84925502690     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2641-3     Document Type: Article

References (13)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24(18):2903-2909
3. Rivera F, Vega-Villegas ME, López-Brea M (2007) Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33:315-324
4. Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435-1442
5. Cunningham D, Starling N, Rao S et al (2008) Upper gastrointestinal clinical studies group of the National Cancer Research Institute of the United Kingdom capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36-46
6. Kang AND, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III non inferiority trial. Ann Oncol 20(4):666-673
7. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24(31):4991-4997
8. Rivera F, Grávalos C, García-Carbonero R (2012) SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clin Transl Oncol 14(7):528-535
9. Evans D, Miner T, Ng T, Akerman P, Harrington D, Martel D, Maia C, Cioffi W, Benton D, Safran H (2006) A phase I/II study of oxaliplatin, docetaxel, and capecitabine in advanced carcinoma of the oesophagus and stomach. Gastrointest Cancer Symp Abstract 67
10. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
11. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
12. Van Cutsem E, Boni C, Tabernero J, Massuti B, Richards DA, Prenen H, Steinberg I, Rougier P (2011) Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. J Clin Oncol 29:suppl; abstr 4018
13. Dong N, Jiang W, Li H et al (2009) Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer. Am J Clin Oncol 32(6):559-563